EBS Emergent BioSolutions Inc

Price (delayed)

$58.80

Market cap

$3.15B

P/E Ratio

8.02

Dividend/share

N/A

EPS

$7.33

Enterprise value

$3.46B

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Highlights

The P/E is 88% lower than the 5-year quarterly average of 66.8 and 62% lower than the last 4 quarters average of 21.2
EBS's gross profit has soared by 68% year-on-year and by 12% since the previous quarter
EBS's quick ratio is up by 19% YoY but it is down by 11% QoQ
Emergent BioSolutions's debt has increased by 9% YoY

Key stats

What are the main financial stats of EBS
Market
Shares outstanding
53.59M
Market cap
$3.15B
Enterprise value
$3.46B
Valuations
Price to earnings (P/E)
8.02
Price to book (P/B)
2.06
Price to sales (P/S)
1.84
EV/EBIT
6.35
EV/EBITDA
5.25
EV/Sales
2.03
Earnings
Revenue
$1.71B
EBIT
$544.9M
EBITDA
$659.9M
Free cash flow
$310.4M
Per share
EPS
$7.33
Free cash flow per share
$5.82
Book value per share
$28.57
Revenue per share
$32.01
TBVPS
$37.25
Balance sheet
Total assets
$2.9B
Total liabilities
$1.38B
Debt
$859.1M
Equity
$1.52B
Working capital
$810.9M
Liquidity
Debt to equity
0.56
Current ratio
3.19
Quick ratio
1.98
Net debt/EBITDA
0.47
Margins
EBITDA margin
38.7%
Gross margin
68%
Net margin
22.7%
Operating margin
31.7%
Efficiency
Return on assets
14.3%
Return on equity
28.6%
Return on invested capital
29.8%
Return on capital employed
21.5%
Return on sales
31.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EBS stock price

How has the Emergent BioSolutions stock price performed over time
Intraday
-1.79%
1 week
-0.51%
1 month
-23.98%
1 year
-30.46%
YTD
-34.38%
QTD
-36.71%

Financial performance

How have Emergent BioSolutions's revenue and profit performed over time
Revenue
$1.71B
Gross profit
$1.16B
Operating income
$540.8M
Net income
$387.3M
Gross margin
68%
Net margin
22.7%
The company's operating margin has surged by 171% YoY and by 14% QoQ
EBS's gross profit has soared by 68% year-on-year and by 12% since the previous quarter
The company's revenue has surged by 54% YoY and by 10% QoQ
The net income has grown by 27% from the previous quarter

Growth

What is Emergent BioSolutions's growth rate over time

Valuation

What is Emergent BioSolutions stock price valuation
P/E
8.02
P/B
2.06
P/S
1.84
EV/EBIT
6.35
EV/EBITDA
5.25
EV/Sales
2.03
The P/E is 88% lower than the 5-year quarterly average of 66.8 and 62% lower than the last 4 quarters average of 21.2
EBS's EPS is up by 27% since the previous quarter
The price to book (P/B) is 43% lower than the last 4 quarters average of 3.6 and 24% lower than the 5-year quarterly average of 2.7
EBS's equity is up by 42% year-on-year and by 5% since the previous quarter
The company's revenue has surged by 54% YoY and by 10% QoQ
The P/S is 44% below the last 4 quarters average of 3.3 and 43% below the 5-year quarterly average of 3.2

Efficiency

How efficient is Emergent BioSolutions business performance
EBS's ROS has soared by 168% year-on-year and by 13% since the previous quarter
EBS's ROIC is up by 21% QoQ
The company's return on assets rose by 20% QoQ
EBS's return on equity is up by 17% since the previous quarter

Dividends

What is EBS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EBS.

Financial health

How did Emergent BioSolutions financials performed over time
The total assets is 111% more than the total liabilities
The total assets has grown by 27% YoY
EBS's quick ratio is up by 19% YoY but it is down by 11% QoQ
Emergent BioSolutions's debt is 44% lower than its equity
EBS's equity is up by 42% year-on-year and by 5% since the previous quarter
The debt to equity has decreased by 23% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.